论文部分内容阅读
目的观察卡铂腹腔灌注联合紫杉醇全身化疗双途径治疗晚期卵巢癌的疗效和不良反应。方法38例均为初治的有可测量病灶的晚期卵巢癌患者,第1、8、15天静脉滴注紫杉醇70mg/m2,第2天卡铂Auc5腹腔内给药,4周为1个周期。结果CR8例、PR19例、SD11例,没有PD病例,近期有效率(CR+PR)为71.1%,中位生存期(MST)36个月。不良反应主要有骨髓抑制、恶心、呕吐,多为Ⅰ～Ⅱ度。结论卡铂腹腔灌注联合紫杉醇全身化疗治疗晚期卵巢癌有效率高、不良反应轻,患者易耐受,值得进一步研究。
Objective To observe the curative effect and adverse reactions of carboplatin peritoneal perfusion combined with paclitaxel systemic chemotherapy in the treatment of advanced ovarian cancer. Methods Thirty-eight patients were all newly diagnosed advanced ovarian cancer with measurable lesions. Paclitaxel 70 mg / m 2 was intravenously administered on days 1, 8 and 15, and intraperitoneally administered on the second day for 4 weeks for 1 cycle . Results CR8 cases, PR19 cases and SD11 cases, no PD cases, the recent effective rate (CR + PR) was 71.1%, the median survival time (MST) 36 months. Adverse reactions are mainly bone marrow suppression, nausea, vomiting, mostly Ⅰ ~ Ⅱ degrees. Conclusion Carboplatin peritoneal perfusion combined with paclitaxel systemic chemotherapy for advanced ovarian cancer with high efficiency, mild adverse reactions, the patient is easy to tolerate, worthy of further study.